Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
From the german yahoo site:
+++++++++++++++++++++
http://de.finance.yahoo.com/q?s=DNAP&d=t&m=F
+++++++++++++++++++++
Indizes Dtschl.: DAX - TecDAX - SDAX - MDAX - mehr...
Indizes USA: DOW JONES - NASDAQ - NASDAQ100
Kurse
WKN/ISIN Namen Deutschland----------XetraFrankfurtStuttgartMünchenBerlin-BremenDüsseldorfHamburgHannover----------USALondonParis----------AmsterdamBrüsselDublinKopenhagenLissabonLondonMailandMadridOsloStockholmVirt-XWienZürich WKN Suche
Ansichten: Basis - Tagesansicht - Performance - Fundamentaldaten - Detailliert - [Neue Ansicht anlegen]
DNAPRINT GENOME (Frankfurt:940906.F/US23324Q1031) - Handeln: Broker auswählen
Letzter Kurs
9:04 · 0,025 Veränderung
0,00 (0,00%) Letzter Schlußkurs
0,025 Volumen
0 Div Datum
24-Nov--13
Klein: 1T 5T 1J keine
Groß: 1T 5T 3M 6M 1J 2J
Tages-Kursspanne
0,025 - 0,025 Geldkurs
0,02 Briefkurs
0,03 Eröffnungskurs
0,025 Ø Volumen
29.758 Ex-Div
24-Nov--13
52-Wochen Spanne
0,025 - 0,09 GpA
0,00 KGV
N/A Mkt. Kap.
16,66Mio DpA
0,00 Rendite
N/A
Chart, Historische Kurse
4% Zinsen aufs Tagesgeld-Jetzt mehr rausholen!
Zum Portfolio hinzufügen Aufbereitet für Tabellenkalkulationsprogramm
Kurse deutscher Aktien um 15 Minuten zeitverzögert. Kursverzögerungen anderer Wertpapierbörsen finden Sie auf unserer Börsenübersicht.
Die Kursinformationen und die europäischen Charts Daten werden von Reuters geliefert.
++++++++++++++++++++++++++++++++++
I would like to be off this!
More on Naked Shorts and Berlin Exchanges
++++++++++++++++++++++++++++
http://www.faulkingtruth.com/article/?Investing101&1005
+++++++++++++++++++++++++++++
Investing 101 - Jun 11, 2004
- Is Dateline Losing Credibility Over StockGate Story Delays?
by Mark Faulk
It's been called the biggest financial scandal in the history of the world, with incurred losses estimated by some experts at well over $1 trillion dollars. It's a scandal that involves over 1,200 offshore hedge funds, over 150 US brokers, and has already bankrupted over 7,000 US companies in the past six years. According to many of the lawsuits filed to date, the crooks include terrorist groups and organized crime syndicates. Sources say that this scandal, which involves an intricate system of selling electronic counterfeit shares of stock in an effort to destroy the market value of small publically traded companies by utilizing a method known as "naked short selling", will eventually implicate almost every major broker in America, all of the governing bodies that oversee trading, and will extend into Canada and Europe. Amazingly, the SEC has admitted it had been "observing" naked short selling for six years, but up to now has done absolutely nothing to put a halt to it.
As The Faulking Truth has written about and followed this story over the past few months, one nagging question has remained: where is the national press coverage on this issue? Aside from a few recent articles in national newspapers, which have barely scratched the surface of this worldwide scandal, why has this been largely ignored by the mainstream media? Why hasn't one of the major network investigative shows put together an in depth expose' to blow this scandal wide open?
Incredibly, we have confirmed that Dateline has done that very thing. According to sources involved with the story, NBC's flagship news program has filmed over 100 hours of explosive footage on the "StockGate" scandal, which includes evidence that will "blow the roof off this scandal". There is only one problem. Originally scheduled to air in January or early February, they have postponed the show repeatedly, and now plan to air it "sometime in August". Even more incredibly, we have learned that they have signed an exclusivity contract with the two law firms that have filed the class action lawsuits that deal with the naked shorting scandal, in effect suppressing the public release of even more information about the scandal.
After publically speaking out about the scandal early on, attorneys John O'Quinn (of the Houston law firm of O’Quinn, Laminack and Pirtle), and Wes Christian (of Christian, Smith, Wukoson and Jewell) have been uncharacteristically quiet for the past few months. That's because Dateline has kept a muzzle on the two attorneys until the "StockGate" segment airs. However, lead attorney Wes Christian has filmed over twenty hours of exclusive interviews for the Dateline segment. Although exclusivity contracts involving the media aren't unusual, this situation is a bit different. This scandal is ongoing, and in fact seems to be accelerating in the past couple of months, even after new NASD regulations supposedly aimed at putting a halt to the corruption went into affect on April 1st.
The shelving of this important expose' by Dateline NBC raises some very important moral and ethical issues, in this writer's opinion. If in fact they have collected information that would help to put a stop to the massive criminal activity that is robbing American companies and their stockholders of literally hundreds of millions of dollars every day, aren't they at the very least morally obligated to release that information in a timely fashion? And since they have postponed the show for the last four months, shouldn't they release attorneys O'Quinn and Christian from their exclusivity contract, so that they can disseminate information that might be vital in helping the victimized companies, their shareholders, and the various governing bodies put to end this ongoing corruption? And if in fact the money being stolen from honest Americans is being used to fund terrorism and organized crime, then shouldn't Dateline immediately make public any information that could help put an end to those insidious activities? Dateline declined to respond to repeated emails inquiries for this article.
The question remains: why has Dateline been so slow to expose this monumental ongoing scandal, even as the corruption continues? There is some debate on that point. Some sources believe that they have "caved in to political pressure from the Right, who see this as a political time bomb for the Bush Administration", while C. Austin Burrell, who has provided litigation and research support to O'Quinn and Christian in their lawsuits, believes that Dateline has it's own political and journalistic agenda, and plans to air the show in August to coincide with the Democratic Convention. The scheduled August air date concerns Burrell as well. "August is a dead month, with half of all people on vacation, and the other half not paying attention. It is not an appropriate month to release a piece with such a business focus."
Still others close to the story say it is the complexity and constantly evolving nature of the story that makes it difficult to edit and air. "Complex and constantly evolving" is an understatement. However, this writer for The Faulking Truth has managed to gather pertinent information and write relevant articles on the topic, and in all honesty, I'm just a guy with a computer and a cell phone who does this in his spare time. Dateline, on the other hand, is, well, Dateline. According to Burrell, "This is not a difficult story, and it needs to get out there now. Dateline has made an important time commitment to this topic, and we simply want to see the payoff for the victims."
Regardless of the reason, the time for full disclosure is now. Dateline NBC owes it to the American people to release what information they have immediately, and if necessary, air a followup segment as the story continues to develop. As the Associated Press and rival CBS show 60 Minutes recently pointed out, "In one month, NBC's signature newsmagazine devoted some five hours of programming to the season finale of 'The Apprentice' and the series finales of 'Friends' and 'Frasier.' " If The Donald, Ross, Rachel, and Fraiser rate five hours of coverage in one month on what is supposed to be a major news show "bringing viewers compelling investigative reports", then surely the "biggest financial scandal in the history of the world" is worth a segment or two.
--------------------------------------------------------------------------------
Tell Dateline what you think about this article:
http://www.msnbc.msn.com/id/3303518/
or email them at Dateline@NBC.com.
--------------------------------------------------------------------------------
For a detailed overview of the stock market scandal, read:
"Financial Terrorism In America"
http://www.faulkingtruth.com/article/?Investing101&1001
More articles on Stockgate:
"Stockgate- A Call To Arms"
http://www.faulkingtruth.com/article/?Commentary&1006
"The Berlin Connection?"
http://www.faulkingtruth.com/article/?Investing101&1004
"Is Canada Robbing America Blind?"
http://www.faulkingtruth.com/article/?Commentary&1001
--------------------------------------------------------------------------------
Editor's note: If you would like to help us spread the word about this scandal, send us an email at info@faulkingtruth.com, asking to be added to our "Stockgate activist list". We will email you only when we have new articles dealing with this issue. Please link the articles everywhere you can, post them on stock message boards, and send them to the appropriate public entites. To enact positive change requires positive action.
+++++++++++++++++++++++++++
Stakddek
Just pokin' around.
+++++++++++++++++
1: Hum Hered. 2003;56(4):151-9. Related Articles, Links
Association studies in candidate genes: strategies to select SNPs to be tested.
Cousin E, Genin E, Mace S, Ricard S, Chansac C, del Zompo M, Deleuze JF.
Evry Genetics Center, Aventis Pharma, 2 rue Gaston Cremieux, CP 5705, FR-91057 Evry, France. emmanuelle.cousin@aventis.com
OBJECTIVE: When numerous single nucleotide polymorphisms (SNPs) have been identified in a candidate gene, a relevant and still unanswered question is to determine how many and which of these SNPs should be optimally tested to detect an association with the disease. Testing them all is expensive and often unnecessary. Alleles at different SNPs may be associated in the population because of the existence of linkage disequilibrium, so that knowing the alleles carried at one SNP could provide exact or partial knowledge of alleles carried at a second SNP. We present here a method to select the most appropriate subset of SNPs in a candidate gene based on the pairwise linkage disequilibrium between the different SNPs. METHOD: The best subset is identified through power computations performed under different genetic models, assuming that one of the SNPs identified is the disease susceptibility variant. RESULTS: We applied the method on two data sets, an empirical study of the APOE gene region and a simulated study concerning one of the major genes (MG1) from the Genetic Analysis Workshop 12. For these two genes, the sets of SNPs selected were compared to the ones obtained using two other methods that need the reconstruction of multilocus haplotypes in order to identify haplotype-tag SNPs (htSNPs). We showed that with both data sets, our method performed better than the other selection methods. Copyright 2003 S. Karger AG, Basel
PMID: 15031617 [PubMed - in process]
++++++++++++++++++++
????
Stakddek
This company requested to be delisted from Frankfurt Exchange:
++++++++++++++++++++++++++++
Press Release Source: Roanoke Technology Corp.
Roanoke Technology Corp. Confirms Request for Delisting on Frankfurt, Germany, Stock Exchange Accepted to Help Stop Shorting
Friday May 7, 11:33 am ET
ROCKY MOUNT, N.C.--(BUSINESS WIRE)--May 7, 2004--Roanoke Technology Corp. (OTCBB:RNKE - News) is pleased to announce that the company's filing to be delisted on the Frankfurt Stock Exchange has been accepted. Therefore, as of today, the company is no longer trading on the Frankfurt Exchange and it is hoped that this will assist in reducing the shorting of our stock.
Roanoke Tech C.E.O, Mr. David Smith commented, "The listing of Roanoke Tech on the Frankfurt exchange was done by a third party without our knowledge and/or approval. When this was brought to our attention, action was immediately taken to have our company delisted and this has now been accomplished."
Note: "Safe Harbor" Statement Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.
-------------------------------------------------------------
Contact:
Roanoke Technology Corp., Roanoke Rapids
Russell Jones, 252/428-0200
-------------------------------------------------------------
Source: Roanoke Technology Corp.
++++++++++++++++++++++
I post this for informational purposes only. I neither recommend or endorse the above company. I do however believe that there is a "different" set of rules for stocks trading on the foriegn exchanges, and that different set of rules tends to put US investors at a disadvantage. I would almost liken it to playing the market with "monopoly money" that has no intrinsic value, while cashing in the profit on the "monopoly money" in US greenbacks. I tend to consider the game unfare when the opponent doesn't risk what I'm risking. Just my 1.5 cents. Can't afford more right now!
Stakddek
Just wondering about that listing for dnap on the German exchange. I have noticed some other companies requesting delisting because the foriegn exchanges "allow" shorting. In fact I understand a few companies didn't even make an application to be listed there. I seem to remember DNAP being listed overseas. Is this shortable listing still extant?
Stakkdek
Orchids new partner, looks to be working in DNAP's area, and cites material back a few years. Any thoughts from our more astute participants???
++++++++++++++
http://www.cybgen.com/technology/technologyframe.html
++++++++++++++
I didn't notice any familiar names but that is simply my being overdrawn at the memory bank!
Stakddek
Mahastock! The only definite in that profile was White Male. Everything else was maybe could be probably. Why do you think the profiler states >IS< a white male? I've gotta think about that one! Holding and waiting on this end. Good Luck to us all.
Stakddek
Re: stories posted on Lee DNA:
I find it interesting that in my read of the stories the legal question was about how the DNA material was acquired from Lee and had nothing to do with the assistance DNAP provided in classifying the ancestral background of the suspect from DNA left with the victims. This doesn't remove DNA Witness from the "legal woods" yet, but the focus in those stories was on how a test sample was collected from Lee. I would guess our day in court will be coming as Mr. Lee's attorney utilizes addittional legal arguments (grasps at straws) to protect his clients rights. It is refreshing that the judge at the hearing wasn't buying the attorney's argument, but I hope he won't be reversed. It would be a shame to see a multiple murder let off by a technical argument undercutting all the other evidence in the case.
Long and strong.
Stakkdek. >Happy Friday!<
PS: thanks to all for the continued great contributions.
Chig you paint a pretty picture. I've seen people on multiple drugs and few pharmacies are really 100% on catching prescriber error. Not to mention herbals etc. The idea that a big blue brother would keep us safe from scribbled scripts and our own stupidity is intriguing. Of course privacy etc. Maybe it's something we can get over. but legislating against the health care and insurance powers requires a lot of courage, or at least a retiring politician. You know they want to know all about us, and even have advised patients that "only" Lipitor" prescriptions will be reimbursed. It's okay I guess, if Lipitor does work for you! Be nice to know if another med would be better. I have always prefferred my physician to prescribe for me, as long as he isnt a paid consultant or enjoying ski trips on my health! The idea that an insurer can "prescribe" by economic dictates is not my idea of good medicine. Dnap could save us all from this, but we all know change can be slow unless you have a big stick. Or, maybe you have a few friends with big sticks. I think we may be gathering a potent force!
Stakddek
OT: Happy Easter to all. Whatever way you celebrate, whatever it means to you. As a kid I liked the jellybeans and egg hunts. As I get older, I appreciate the chance for family gatherings and phone calls to distant relatives and friends. I never was super heavy on religion because to me it's personal. I can understand people having doubts, and others having no doubts. I am happy with me, and I hope all of you are happy with yourselves and who you are. Now all of you count your blessings, or jellybeans, and let's get back to DNAP. Happy Easter.
Stakddek
CMIH NEWS! 1000/1 Reverse /Symbol/name change >RFMR Acquisition Corporation with symbol RFAC.PK<
All I know.
Stakddek
Tam and Especially Wonderful Sister, Thank you, thank you both. For wonderful sister to attend for DNAP and IBM and Moffet was a chore she really has all our thanks for. For enduring the software companies, and fighting on to the bitter end, you are to be heavily commended by all here. You went far beyond the call of dilligence to interview Mr. Gabriel and others from DNAP. I hope someday the company will realize just how dedicated and helpful many of the shareholders are, not only to each other but to DNAP as well. Thank you.
Stakddek
Hi all. Haven't had much to offer in the way of DD, but have been watching. Pretty much gave up on RB and only check here on occassion. Recent news re Witness activity and now this very visible cancer medication screening is great. Frog even suggests DNAP has been brought up from the farm team! OF course he sees his swamp as still 1/2 empty. I'm still in for the full pot, and am looking forward to more significant news about DNAP. Let's hope the testing goes smoothly. WE are all impatient as shareholders for sucess, but we have to remember there is an awsome responsibility in directing a patient away from one form of treatment and make them rely on another. This is a much higher stakes game than just money, so let us all understand none of the medical people involved will be praising DNAP until they are 100% certain of it's value. At least now we are seeing some wilingness by a major player to proceed on the notion that DNAP might just have something of very great value.
I'll be standing out here in the parking lot behind the centerfield bleachers. I've got my glove on my hand and I'm ready to catch that long one Doctor Frudakis is going to hit. DNAP is in the lineup. This will be an interesting baseball season!
Stakddek
Toronto Star story re: cancer research
http://65.54.170.250/cgi-bin/linkrd?_lang=EN&lah=261e9975ffd9d9546d58a44225177b51&lat=107982...
Mar. 20, 2004. 01:00 AM
Canada's high-tech cancer fight
A pioneering Vancouver research centre probes ways to treat and, possibly, prevent cancer Scientists are building on the discove
PETER CALAMAI
VANCOUVER—Every morning as they arrive at work, Canada's crack team of genome cancer researchers gets a new jolt of motivation.
That's because to reach their cramped quarters at the Michael Smith Genome Sciences Centre on the third floor of the B.C. Cancer Agency here, the researchers must walk past dozens of clinic out-patients, whose drawn faces hint at the toll of the disease.
Yet, it's quickly obvious from interviews that the genome centre's staff are already highly motivated to find better ways to detect and treat cancers, and eventually prevent them, even without this daily personal reminder of the human stakes.
The patients represent far more than extra motivation anyway. Tracking the detailed genetics of the clinical condition of cancer sufferers is vital to the most exciting work in a facility that is one of Canada's newest powerhouses of scientific discovery.
Ontario residents probably first heard of the centre last April when, after a six-day, around-the-clock blitz, researchers here produced the first genetic blueprint of the SARS coronavirus, posting it on their Web site for scientists everywhere to use.
That's unlikely to be the last time the centre snares headlines. Pioneering research currently underway includes investigation of the potential for preventative vaccines against cancer, the deliberate triggering of the body's own "angels of death" to destroy tumours and a large-scale study of how genetic and environmental factors interact in non-Hodgkin lymphoma.
Named after the late Canadian Nobel chemistry laureate, the Michael Smith centre is tackling cancer with two weapons that promise to revolutionize treatment — the profound findings and powerful techniques from the human genome project.
It's less than a year since this international effort published the final human genome "sequence," the order in which three billion linked chemical pairs are arranged in our genetic blueprint, the shop manual to build and operate every cell in the body.
Already, the techniques derived from the human genome project are being used at the centre to decipher the genetic blueprints of everything from spruce trees, to salmon, cows, lab mice and rats, bacteria and even wine grapes.
"We're just beginning to see all the different programs that can make use of the expertise at the genome centre," says Alan Winter, president and chief executive of Genome B.C., regional partner of the federally funded Genome Canada.
Over the last three years, Genome B.C. has directed $33 million to the Genome Sciences Centre, representing a quarter of the provincial agency's total grants. Winter sees the centre as a catalyst for life sciences in the province with a potentially large economic pay-off.
At the facility itself, however, cancer work is the priority and it's what truly gets the researchers talking.
"The patients help give us a sense of what we're capable of," says centre director Marco Marra.
Marra radiates enthusiasm and energy as he describes the centre's world-ranked expertise and unique research mission in Canada. Outside his modest office, the lab wall is adorned with four-by-six prints of the centre's 134 staff members. Even the senior researchers appear incredibly young.
"The average age is probably well below 40, a lot like you'd find at a university," says Marra, 37.
In research capability, the Genome Sciences Centre resembles university institutes as much as Tiger Woods resembles other professional golfers. The formidable scientific arsenal here includes:
The largest genomics centre in North America dedicated to cancer research.
The highest-capacity genome sequencing lab in Canada, with enough power to sequence the gene portion of human DNA 10 times over in a year.
The world's leading laboratory for the crucial sequencing step known as genome fingerprint mapping. This has been compared with determining the order of the pages and volumes before starting to read an encyclopaedia.
Canada's leading academic group in terms of computing power and resources, with more than 200 individual computing devices, a "cluster" that does supercomputing tasks at electronics superstore prices and seven terabytes of online storage. (A terabyte equals 1,024 gigabytes.)
The country's largest academic concentration in bioinformatics, the discipline of managing, analyzing and digging into Everest-sized mountains of biological data.
"There is no traditional way you could handle the data sets that are being produced here. The files are so large that you couldn't even print them out," says Steven Jones, 35, who is in charge of the bioinformatics operation. "People are now doing biology in a way that was never possible before."
This new approach isn't simply a matter of raw computing power, although Jones shows off an air-conditioned room where indicator lights blink spastically from racks holding 80 twinned CPUs, the brains of a computer.
"That computer can do one gene, while that computer does another," he says. Equally important are the instructions for the CPUs, called algorithms, custom-written by the bioinformatics staff of 60 who also devise special graphics software. And these aren't geek computer programmers. Twenty-eight hold graduate degrees, many from the biological sciences plus mathematics and astronomy, disciplines where the data arrives in continuous tsunamis.
One of their visualisation programs, called Sockeye, gives the researchers a 3-D image of where the same gene is probably found in different organisms. The coloured lines enveloping Jones in the photograph, above, pinpoint the likely locations of a common cancer-related gene, called p53, within human, mouse, rat and zebra fish DNA.
"You can buy sequencing machines, you can buy computer equipment. The various doodads aren't rate-limiting," says Marra, using an analogy to the key factor that controls a chemical reaction. "What is hard is finding talented people."
It's exactly in this area — which Marra calls intellectual bandwidth — that the Genome Sciences Centre really shines.
Take the centre's director himself. Born and educated here, Marra was attracted 10 years ago to Washington University in St. Louis, where he played a leading role in the human genome project. His name is second among the more than 100 authors of the landmark 2001 scientific paper that announced the successful preliminary mapping of the human genome.
----------------------------------------------------------------
`The (cancer) patients help give us a sense of what we're capable of'
Marco Marra, cancer genetics researcher
----------------------------------------------------------------
Lured back to Vancouver in 1999 when the centre was begun by Smith and Victor Ling, head of the B.C. Cancer Research Centre, Marra now finds himself trying to keep tabs on two dozen research projects here in contrast to the two or three huge projects tackled at Washington University.
As well, while the centre has been successful in attracting government grants for specific projects, like the bovine genome, and for costly equipment like $600,000 DNA sequencers, Marra says there is some concern that staff salaries depend largely on public fundraising by the B.C. Cancer Society.
"You can't have a vision based on a three- to five-year time frame," he says. At the same time, there appears to be no lack of vision at the Genome Sciences Centre, or of top-notch scientists pursuing research with a potential for big payoffs.
Consider 35-year-old Rob Holt, another example of "brain return" at the centre.
The B.C.-born Holt was a star at Celera Genomics, the American private sector competitor in the human genome race, where he helped pioneer a superfast "shotgun" sequencing method.
In October, 2002, Holt was the lead author of the scientific paper that laid out the genetic blueprint for the malaria mosquito. A week after that was published, he arrived here to oversee the centre's sequencing operations.
That would be a full-time job for most people, especially with regular improvements in quality control and cost reductions. But Holt is also pursuing three independent research investigations, including continuing the malaria work plus probing possible genetic factors in schizophrenia and bipolar disorders.
The potential big payoff, however, involves searching for a vaccine against colorectal cancer. "In cancer research, people are only just beginning to explore the idea of prophylactic vaccines," Holt says.
The approach is relatively straightforward: Find the common gene mutations responsible for a certain cancer, isolate them and then insert them back into the organism being tested, starting with lab animals.
"We're trying to fire up the immune system before it is too late," Holt says. In collaboration with Dr. Isabella Tai, a gastroenterologist, Holt is testing the approach by giving cancer-causing chemicals to a strain of mice already prone to colitis.
The researchers will then create genetic profiles of the tumours that develop in the mice and try to pinpoint the responsible gene mutations.
Holt acknowledges that meaningful results from the mouse studies will probably take a couple of years. "But we could have something that would actually prevent a cancer," he says.
In another cramped corner of the lab, Angela Brooks-Wilson is equally enthusiastic about the potential benefits from her research into non-Hodgkin lymphoma. As head of the centre's cancer genetics effort, the 41-year-old researcher is intrigued by the question of susceptibility to cancers.
"There are people who smoke heavily all their lives and they don't develop cancer. And then there are people exposed to second-hand smoke, and they do," she says.
Clinicians and epidemiologists at the cancer agency had a similar interest in susceptibility and also a long-standing program focusing on non-Hodgkin lymphoma, a form of cancer more prevalent in agricultural workers exposed to pesticides.
So the groups teamed up in a project just getting underway that will genetically compare 750 non-Hodgkin lymphoma patients with an equal number of matched people free of cancer.
That number is large enough, says Brooks-Wilson, that the research should be able to detect a genetic factor that increases the risk of developing the cancer by as little as 50 per cent. Because of natural variations and other uncertainties, epidemiologists usually pay attention only when factors appear to double the risk, a 100 per cent increase.
But statistically teasing out possible effects from environment influences like pesticides combined with genetic factors needs a much larger sample, only possible by adding results from other similar research.
"It's most likely going to prove to be a combination of genes that give a genetic susceptibility, plus environmental factors," Brooks-Wilson says.
In addition to gaining new insights into the biology of cancer and promoting the use of state-of-the-art technology, the centre's mission also encompasses the training of new top-drawer researchers in bioinformatics, cancer biology, genomics and molecular biology.
One of 14 current trainees is Sharon Gorski, a 39-year-old post-doctoral fellow working with Marra on a biomedical topic known as programmed cell death.
Genetically encoded signals in the body arrange for obsolete or damaged cells to self-destruct, just like a spy swallowing the traditional suicide pill.
There are two different self-destruction methods and Gorski's research focuses on the least understood — autophagy, which means the cell eats itself, dissolving from the inside out. It's this process that eliminates the residual webbing between the fingers on the hands of human fetuses in the womb.
"It's an appealing model if you wanted to get rid of a tumour in the quickest way possible," Marra says.
Yet, autophagy is complicated, acting in some cases as a protector of cells and in different circumstances as a killer. Gorski says autophagy probably plays a role in prolonging the survival of cancerous cells in the centre of solid tumours. The absence of blood vessels in the tumour interior means such cells would normally expire from a lack of nutrients.
By dissolving the damaged bits of these interior cells, autophagy provides a substitute source of nutrients to keep the cell alive. Similarly, the self-destruct mechanism may get rid of components in cancer cells that have been damaged by chemotherapy or radiation. That removal would prevent apoptosis, the better-known form of programmed cell death, from kicking in.
"We need to know the genes involved in autophagy and the molecular pathways," Gorski says.
To unravel these genetic mysteries, Gorski has turned to the fruit fly. As the fly matures from the pupae stage, autophagy destroys the salivary glands. Using the sophisticated arsenal of techniques developed in the human genome project, Gorski is slowly homing in on some of the genes responsible.
Before her work is finished, the Michael Smith Genome Sciences Centre will have moved twice — first, next month, to a building a few blocks away that has enough space to house the bioinformatics researchers currently working out of other offices in Vancouver, and then, in 2005, to a combined new home with the B.C. Cancer Research Agency.
So, cancer patients will still be around for a jolt of motivation — not that the researchers are likely to need it.
Migwan0: Thanks again. You are a master at fitting those little (and big) pieces into out favorite jigsaw puzzle.
Glad to see the J+J comments. Seems like if the FDA doesn't "do the right thing" and quick, the companies are becoming aware enough to utilize biogeographical ancestry themselves. Might just need a DNA ancestry test to exclude patients who might see no benefit or be harmed by some new drug.
Wouldn't it be interesting for some drug manufacturer to report to the FDA "100% effective" when applied to this biogeographical group with these allelle sets.
The question comes to mind, that if I decided to take a test to map my distinctive markers for drug efficacy, would that "map" be applicable across a broad spectrum of drugs? Would of course refer to "what's the best pain reliever for me?" - whay's the best statin medicine for me? Blood pressure? Diabetes prevention. Would one test "for me" allow comparison agains clinical trial groups "maps" to see if I could benefit from current or future drugs?
I would like to imagine that one day I could go to the local pharmacy and "swipe my DNA profile card" for the best over the counter remedies for my use. Of course the real pay-off would be having the card for my family physician to swipe before he wrote a prescription for my needs. Who knows, he might even need to rewrite some scrips for what I'm taking now.
I can grant that new discoveries and interactions will outdate the early dna profiles as new markers and thier significance are uncovered. I would conjecture that the process would be additive, and may lead to the ability of the FDA to speed needed "smart drugs" to market, as long as a biogeographical screening is done on the patients. Thinking ahead, i would love to see the day when my medical insurance provider required a DNA screen to be done so the most cost effective and result effective combination of treatments would be used. With the aging of America, the numbers of patients requiring "senior care" medications will skyrocket. Careful management is required now to look for drug interactions within the range of medications prescribed for one patient by perhaps 5 or 6 different doctors attending. The pharmacist is the last link in the chain, because he is usually the dispenser of all the medications that are prescribed from different sources. I don't think it is too far out of line to hope that one day the dna profile will become a useful tool not only at the "doctor-patient" level but at the "consumer-pharmacist level as well.
Johmson and Johnson comments you noted may be an early sign that the companies are paying a great deal of attention to the discreprancies betwen biogeographical dna mapping and "self reported racial profiles.
Stakddek
Well at least he snuck the buys in!
Stakddek
Chig and Chris. We got a dumbe club! Or maybe we are the "wascally wabbits"!
Stakddek
Lauty: Some have played it as a short term play on movement while maintaining a core position, Some of us (I think just me) are to dumb to know when to sell at a peak or buy at alow. We just accumulate and ride the rollercoaster, because we see the long term outlook as positive. You might consider an investment practice that makes you happy, but whatever you do, don't bet the farm on any one stock. Many of us are holders over two years. During that two years we've seen all kinds of action. Some with nerves of steel have played it for the short term gain. When you factor in the tax on short term capital gains, it hasn't been worth the risk of missing the boat if we set sail for our expected trip to the moon. You have to play all these stocks with how you are comfortable. Good luck in your investing and thanks for considering DNAP as one of your vehicles.
Stakddek
My read on one of them was that if a broker didnt provide the shares of stock AAAA by the due date, they would be prevented from trading in AAAA shares. I read it to mean they could just go to BBBB stock or CCCC stock and do the same thing. Given the universe of stocks out there, they can rotate and still have lot's of stocks to short. I hope I read this wrong and interptetted it incorrectly. I guess I sound sour about the system we have.
Do MM charge vapor commissions on vapor shares?
Stakddek
Bravo Miss Scarlett. You're being a bit under the weather has not impaired your ability to espress the feelings of many posters here. I hope we all feel much much better very soon.
Chicken Soup
Stakddek
PS MAybe some cocanut cream pie too. ( But that makes some people hyper)
<><><> PRESS RELEASE FROM USGA <><><>
Press Release Source: US Global Nanospace
US Global Nanospace, Inc. Investor Update
Tuesday February 3, 2:52 am ET
CARSON CITY, NV--(MARKET WIRE)--Feb 2, 2004 -- US Global Nanospace, Inc. (OTC BB: USGA) today released the following investor update.
A third party recently published misrepresentations regarding US Global Nanospace in what we consider to be a malicious effort to temporarily discredit our company for short-term financial gain. We believe this effort was perpetrated by a coordinated group comprised of a website that circulates negative information about publicly traded companies to its paying subscribers in advance of releasing the information publicly and certain internet chat board posters. We have contacted and requested assistance from applicable law enforcement and government agencies to bring the perpetrators to justice and have provided information for them to do this. US Global is among many other corporate victims that these people have attacked and we are now preparing to begin a dialogue with these companies to form a coalition against such further attacks.
We have received significant support from many of you and thank you for your confidence in us. We assure you that we are exploring all our legal remedies against the perpetrators of this malicious act and we will not rest until the company and its stockholders have been made whole.
We realize that the complex nature of our materials and technologies can be confusing and sometimes misunderstood. In our continuing attempt to clarify our technological achievements and challenges, we have updated our website at www.usgn.com so you may continue to make informed investment decisions regarding the company.
Specifically, we have listed information regarding patents and provisional patent applications licensed to or owned by US Global Nanospace below and on our website at www.usgn.com/pats.pdf. Also, supplemental information about our All-Clear decontamination foam and historical notes about our Enhanced Security Cockpit Door program follows the patent information below.
NanoFilterCX
US P* Patent Application 60/481,111 filed July 21, 2003.
International patent filed with a priority date of July 21, 2003.
NanoFilter
US Patents utilized per Patent/License agreement on file:
5,368,635 issued November 29, 1994
5,540,761 issued July 30, 1996
5,647,890 issued July 15, 1997
5,855,653 issued January 5, 1999
Plus all respective international patents.
All-Clear
US Patent Application utilized per Patent/License Agreement on file:
2003/0109017 Filed June 12, 2003
Ballistic Impact resistant Nano-denier fiberous Woven sheet
US P* Patent Application 60/327,684 filed 10-6-01
Intl Patent Application PCT/US 02/12241, 4/15/2002
Anti-ballistic, lightweight Secure cockpit door
US P* Patent Application 60/349,988 filed 1-23-02
Intl Patent Application PCT/US 02/12055, 4/15/2002
Anti-ballistic, wide Angle peep-hole viewer
US P* Patent Application 60/349,990 filed 1-23-02
Intl Patent Application PCT/US 02/12053, 4/15/2002
Security Cockpit door; Integrally vented, pressure Equalized
Intl Patent Application PCT/US 02/12054, 4/15/2002
S.A.G. Turret
US P* Patent Application 60/481,080 filed 7-11-2003
P* - Provisional
All-Clear and EPA Regulation
US Global Nanospace recently provided a "tech-brief" to the Technology Support Working Group (TSWG), a group that supports technology for use by the military in the fight against various forms of terrorism. Providing tools to mitigate the threat of chemical and biological warfare (CBW) agents is one of the TSWG's goals. The TSWG had posted USGN's tech brief at www.tswg.gov, but removed the brief after a couple of days. The TSWG removed the tech brief pending our response to its request that we provide a clearer description of the capability of All-Clear and that we provide language that explains how the Environmental Protection Agency (EPA) regulates biocides under the Federal Insecticide Fungicide and Rodenticide Act (FIFRA). The EPA enforces FIRFA by classifying biocides and reviewing related company claims and instructions for product use. In order to register a biocide for sale and use within the U.S., the EPA requires that these products be proven as a sterilant via the AOAC Sporicidal Test. The EPA then determines whether the biocide should be granted emergency exemptions to remediate potentially contaminated areas. The EPA believes this to be the best way to ensure efficacy based on company claims and address biological weapons threats. It must be kept in mind that CBW agents are a relatively new threat to U.S. soil, and that the excessive toxicity and hazardous nature of previously used CBW decontamination solutions used by the military present ecological and corrosive challenges that the EPA must consider in balance with other U.S. regulations. We provided a revised tech brief to the TSWG for re-posting on its website and it is reviewing final language to comply with the EPA's request for labeling and suggested use of our All-Clear product.
It is important to further explain the specifics of the AOAC Sporicidal Test and how this test relates to testing All-Clear against anthrax. All-Clear has been tested at IIT Research Institue (IITRI), a biosafety level 3 laboratory (BSL 3) in Chicago, Illinois. As a BSL 3 lab, IITRI is approved to accomplish validation testing of products against actual strains of anthrax as well as actual chemical weapons agents. The testing at IITRI has shown that within sixty minutes, All-Clear is extremely effective in killing bacillus anthracis and in destroying G-type nerve agent. However, as stated above, the EPA standard for registration of a biocide as a sterilant is the AOAC Sporocidal Test, using two surrogates to bacillus anthracis -- bacillus subtilis and clostridium sporogenes. This provides the EPA with a means to test solutions against similar, but less hazardous spore forming organisms like bacillus anthracis in a safer environment. A lab following EPA-recognized protocol will be utilizing the AOAC Sporicidal Test, which will take approximately six weeks from this date to complete.
Thus, the TSWG's request for additional language in our tech brief should not be regarded as an indication that All-Clear is not effective against Anthrax. The IITRI testing has shown that it is. However, until the EPA develops a testing protocol that specifically uses strains of bacillus anthracis, they will rely on the historically used benchmark provided by the AOAC test. For this reason, we believe that the IITRI testing that shows effectiveness of All-Clear against the real threat is the most important point of this discussion. That said, the AOAC protocol is part of the effort to fully register All-Clear, and we continue to work with the EPA so that this can be accomplished.
As an aside, and reminder, All-Clear is not only a biocide in the specific remediation of Anthrax, but also is a chemical weapons remediation tool as supported by the IITRI testing. If there were to be an attack (and hopefully before such), we remain confident that All-Clear can be deployed as an effective chemical weapon clean up tool, which would be outside of EPA regulation under FIFRA, but would comply with ecological concerns, as the components of All-Clear were, from the start, chosen to be non-toxic and environmentally friendly.
All-Clear and Mitigation of Mad Cow Disease
Our detractors have mocked the use of our All-Clear product for BSE, or "mad cow disease". We recognize BSE is a serious disease in its link to vCJD (variant Cruetzfeldt-Jakob Disease), which is lethal in humans, and its large potential to damage the beef industries in the U.S. and abroad. We would like to reiterate that we do believe that "All-Clear" can be expanded to include remediation of agro-terrorism or pesticide threats and to mitigate other livestock or agricultural risk from diseases such as Mad Cow (BSE), hoof and mouth or bacterial wilt. Until an effective preventative solution for this and other such threats to our society are effectively developed we will continue to strive for solutions to minimize ongoing environmental contamination.
The following excerpts (with links provided) state that the infectious nature of transmissible spongiform encephalopathies (TSE), including Mad Cow Disease, is still under debate. If a viral agent is indeed part of the not-yet-fully-understood reproduction of prions, which are recognized as the key causal agent of TSE's, it is possible that All-Clear can be of use in the mitigation of threats from Mad Cow disease. Despite the irreverent way the third party has referred to the use of All-Clear in mitigating BSE, the point is made that it is not reasonable that All-Clear is ready to be used as an internal medicine to treat TSE. Obviously, such use would be quite a length of time away (probably years), and would need extensive FDA study and review. On the other hand, processing and disposal of BSE infected meat remains an issue, and the Food Safety and Inspection Service department of the USDA wants less corrosive, less toxic sanitation methods (see reference below). So, we think it is indeed wise and fair to offer that All-Clear deserves review if expansion of the formula can help mitigate a threat that so far isn't completely understood. This is not only true in that All-Clear can be an effective virucide, but also in that the chemical weapons remediation component of All-Clear may have significant promise in disrupting prion activity. As stated, the testing and proof of this would depend in part on the determination of the severity of the threat that BSE places on our economy and health, and the immediacy of placing safeguards within the system.
From The British Medical Bulletin, 2003
"Introduction to the transmissible spongiform encephalopathies or prion diseases,"[by] Chesebro B., Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institutes of Allergy and Infectious Diseases, Hamilton, Montana 59840, USA.
Sheep scrapie has been known for at least 200 years and was described as a
transmissible disease over 100 years ago. Since then, three groups of
transmissible spongiform encephalopathies or TSE diseases have been
identified in humans including familial, infectious and sporadic types. The
discovery of the prion protein (PrP) in the 1980s greatly accelerated
knowledge of the biology and pathogenesis of TSE diseases as this protein
was found to play a critical role in disease susceptibility and the TSE
species-barrier and may also be a component of the infectious agent itself.
Nevertheless, the nature of the TSE agents remains an enigma. Proof of the
protein-only hypothesis may require generation of biologically active
transmissible agent in a cell-free environment where a virus cannot
replicate. Conversely, proof of a viral aetiology will require
identification and isolation of a candidate virus. Further understanding of
the structure of the disease-associated protease-resistant PrP should help
elucidate the mechanism of PrP conversion from the normal to the abnormal
form. Such information should open up new approaches to both diagnosis and
therapy.
From http://www.gao.gov/new.items/d02183.pdf
The prion hypothesis is not universally accepted. Some scientists believe a
virus or other conventional agent, as yet undetected, gives rise to
TSEs.
From http://www.sciencemag.org/feature/data/prusiner/214.shl
Key questions remain, however. "The most important bit of information has
yet to come forward: What triggers the normal cell protein to transform
into the [disease-causing] isotype of the protein?" says Clarence Gibbs, a
virologist at the National Institute of Neurological Disorders and Stroke
and a longtime colleague of Gajdusek. (Prusiner addresses part of that
question on page 245, where he suggests that a possible missing element,
dubbed protein X, might help chaperone the PrP protein into its infectious
shape.) And no one has been able to inject a prion protein synthesized in
the test tube--and therefore free of any possible contaminating virus or
other nucleic acid--into a healthy animal and make it sick." says Laura
Manuelidis, a neuropathologist at Yale University who has argued that a
virus or other particle is involved. Prusiner acknowledges that there are
still many uncertainties. "There are all these other experiments that
should be done," he says. "I want to know more about all these
details."
From http://www.fsis.usda.gov/OA/topics/BSE_Thinking.pdf
FSIS believes that it would be prudent to develop methods that could
prevent the CWD [Chronic Wasting Disease] agent from contaminating
equipment used to slaughter livestock subject to mandatory Federal
inspection. The agents that cause BSE, CWD, and other TSE's are highly
resistant to heat, ultra violet light, ionizing radiation, and common
disinfectants and FSIS is not aware of any practical methods that could be
used to sanitize equipment that has been contaminated with a TSE agent.
Certain sanitation measures, such as treatment with sodium hypochlorite
(20,000 ppm of available chlorine) and treatment with hot 2N sodium
hydroxide solution for one hour, appear to be effective. But these
sanitation methods are harsh on equipment and can be hazardous. FSIS is
interested in receiving any scientifically based information on this
subject.
The Guardian Cockpit Security Door
US Global Nanospace's Guardian Door was in our opinion a technological success, although for the reasons we will summarize below, it has not been a commercial success for the company. For those of you who are uncertain of the facts regarding our Guardian Door, we would like to reiterate that this enhanced cockpit security door contained unique technological features that provided, in the opinion of the Israeli Services Protection and Security Division, a superior level of security to the cockpit and its crew. In fact, it was the only door to pass their tests, which actually include a real blast test, not one simulated by a shot from a 9mm like that of the FAA. We initially teamed with Raytheon, which later became L-3 via acquisition. Raytheon/L-3 was an ideal partner at the time because in addition to having a large work force (approximately 500 at that time) available for the project, they were also an FAA Designated Alteration Station (DAS), which gave them the authority to issue a Supplemental Type Certificate (STC). Many of the quotes that have been made in reference to our development schedule and projections were based on the working partnership with Raytheon/L3.
However, due to the high profile nature of this project for the Federal Aviation Administration (FAA), and the fact that FAA understanding of the security issue and design criteria changed frequently, the FAA decided that no DAS would be allowed to issue an STC for cockpit doors and that consequently final approval authority for all modifications would remain within the FAA offices.
These events led the company to focus on the air cargo carriers, which represented a significant niche market that was not being vigorously pursued by the OEM's. In an April 2003 Memorandum the FAA granted regulatory relief to the all-cargo transport category airplanes (document # FAA-2001-10770) effectively exempting them from the enhanced security cockpit door requirement. At this turn of events, the company reluctantly accepted this fate and recognized that in the process of developing the Guardian Door we had created several innovations that on their own have been the foundation of new products with very large market potential.
Conclusion
During the past 12 months we have released details about new products and technologies about which we remain optimistic, and we continue to work in areas where we believe the capacity for innovation exists. We are especially optimistic about disruptive technologies that have the potential to radically change the way problems are solved, whether by dramatically increasing product effectiveness, or delivering savings in cost or energy. In closing, we ask that you question the source of allegations against us, consider the underlying motives of those making such allegations, and give us the opportunity to clarify any misconceptions, before reaching any conclusions. We remain committed to our mission and truly appreciate those who support us.
About US Global Nanospace
US Global Nanospace, Inc. (OTC BB: USGA) is an applied nanotechnology company focused on developing products for commercial and defense applications to enhance and save lives. US Global's materials and products include G-Lam, G-Lam-C, NanoFilters, NanoFilterCX, All-Clear Chem/Bio Decon Foam, S.A.G. Turrets, GARDS HumVee Doors, BlastX, G-Armor and RadomeX. More info is available at http://www.usgn.com.
Contact:
Contact:
Rich Schineller
973.960.6962
rich@usgn.com
------------------------------------------------------------
Source: US Global Nanospace
++++++++++++++++++++++++++++++++++++++++++
Stakddek
Hi All. OTher irons in the fire right now for me but feel DNAP is reaching "critical mass". Someone has to pay for all the startup and infancy stage expenses, but DNAP is precocious. There are irons in the fire here too. Soon one, two or a few will make the joy of helping parent this prodigy the joy it should be.
I still can't post on RB, or reply to a post, or review a posters history. Am I being punished over there for being quick on the mouse and zapping the ads? I had no TOS e-mail so I guess it's just a mess-up with the deletion of some of the community boards they dumped.
Take care and hold tight. It may be a roller coaster ride at first, but I think Doctor Frudakis and his management team are ready for that. February is a "short" month, but don't let them get you down!
Stakddek
Metric conversion Chart How big is???
INCHES TO MILLIMETER CONVERSION CHART 0 - 66”
in. mm. in. mm. in mm. in. mm. in. mm.
0.001 0.0254 1 25.4 28 711.2 41 1041.4 54 1371.6
0.002 0.0508 2 50.8 29 736.6 42 1066.8 55 1397.0
0.003 0.0762 3 76.2 30 762.0 43 1092.2 56 1422.4
0.004 0.1016 4 101.6 31 787.4 44 1117.6 57 1447.8
0.005 0.1270 5 127.0 32 812.8 45 1143.0 58 1473.2
0.006 0.1524 6 152.4 33 838.2 46 1168.4 59 1498.6
0.007 0.1778 7 177.8 34 863.6 47 1193.8 60 1524.0
0.008 0.2032 8 203.2 35 889.0 48 1219.2 61 1549.4
0.009 0.2286 9 228.6 36 914.4 49 1244.6 62 1574.8
0.01 0.254 10 254.0 37 936.8 50 1270.0 63 1600.2
0.02 0.508 11 279.4 38 965.2 51 1295.4 64 1625.6
0.03 0.762 >12 304.8< 39 990.6 52 1320.8 65 1651.0
0.04 1.016 13 330.2 40 1016.0 53 1346.2 66 1676.4
0.05 1.270 *14 355.6*
Now someone be a sport and get out the old slide rule and give us the increase in surface area going from the 300mm wafer size to 355mm? And what's the significance in terms of yield?
Display's will be great, but the money that made profit for the company "despite" R&D in other areas was the furnaces sold capable of allowing larger wafers.
Am I on the right track here with this thought?
Stakddek
Sorry, couldn't format table.
12" = 304mm
14 = 355mm
65 nanometer chips at IBM/ Fishkill NY. Getting closer?
(Hope IBM doesn't import furnaces from England to make substrate.) (Hey I don't even know if it reguires wafers!)
+++++++++++++++++++++++++++++++++++++++++++++++
Infrastructure News
February 2, 2004
Sony Invests in IBM Chip Foundry
By Sean Michael Kerner
Sony will pump $325 million in IBM's Fishkill, N.Y., chip foundry. The investment is part of Sony's continuing partnership with IBM to develop next-generation 65-nanometer chips for its consumer electronic devices.
"The deal is consistent with both firms' strategies to partner to bring these advanced products to market," Sumit Sadana, director of strategy and technology for IBM's Systems and Technology Group told internetnews.com.
The first chip produced by IBM's 300mm semiconductor manufacturing facility for Sony will be codenamed the "Cell" microprocessor. Pilot production is expected to begin during the first half of 2005.
"The way Sony is positioning this is really as a key building block for all kinds of consumer devices," Sadana said, explaining the origin of the codename.
Sadana characterized Sony's investment as 'non-trivial,' noting that any 300mm facility of even minimal scale costs between $2 billion to $3 billion dollars to build.
This announcement is not the first from the Sony-IBM partnership. The two firms, together with Toshiba, have been involved in the design of the "Cell" microprocessor since at least April. A that time, it was reported that the chip would become the engine behind the greatly anticipated Playstation 3.
IBM (Quote, Chart) has now won the "triple crown" of the video game market, according to Sadana. Big Blue currently has relationships with Sony, Nintendo and Microsoft.
"Clearly we don't have an exclusive relationship with any one company, but we certainly have a very good relationship with each of these companies," he said.
"It's not that we're offering all of these companies off-the-shelf products, which prevents any differentiation," Sadana said.
"We're customizing each and every product to the needs of our customers and that is the reason it is not inconsistent to have a relationship with all three of these companies," he said.
"The Sony/IBM partnership is much like some of the other partnerships we are driving with some of our other key customers," Sadana said. "We look to continue to deepen the relationship further and we view this as another excellent building block of that partnership."
IBM's Fishkill, N.Y., plant located not far from Big Blue's Armonk, N.Y., headquarters, which was opened to much fanfare in July 2002. It recently won a new semiconductor order from Taiwan's VIA Technologies.
Sony's investment in the Fishkill facility is part of a $1.14 billion initiative announced today in semiconductor fabrication. In addition to the IBM investment, Sony will invest in its own SCEI's Fab2 semiconductor fabrication facility and a newly built Toshiba plant.
++++++++++++++++++++++++++++++++++++++++++++++++++++++++
Video Links: All real Player
Pokey modem:
http://www.biggerhammer.net/barrett/50cal28k.rm
Good connection:
http://www.biggerhammer.net/barrett/50cal56k.rm
How much a month!
http://www.biggerhammer.net/barrett/50calt1.rm
This is purported to be the "Waxman hearings Video" from the Marine Sniper School.
Stakddek
What is a 50 Caliber Round capable of?
http://www.house.gov/reform/min/pdfs/pdf_inves/pdf_guns_50_cal_marine_transcript.pdf
Having used one, I can say that they are very impressive to whoever they are aimed at. The Browning we used was pole mounted and would shake the entire 80 feet of the landing craft it was mounted on. The comment made to me was "If you can see it you can hit. If you can't see it you can dig it out."
I'm trying to find a good link to the video.
Stakddek
Patents from USGN Website from PDF file as text
The pdf link:
http://www.usgn.com/pats.pdf
++++++++++++++++++++++++++++++++++++++++++++++++++++++
Current & Provisional Patents, Applications & Licenses
NanoFilterCX
US P* Patent Application 60/481,111 filed July 21, 2003.
International patent filed with a priority date of July 21, 2003.
NanoFilter
US Patents utilized per Patent/License agreement on file:
5,368,635 issued November 29, 1994
5,540,761 issued July 30, 1996
5,647,890 issued July 15, 1997
5,855,653 issued January 5, 1999
Plus all respective international patents.
All-Clear
US Patent Application utilized per Patent/License Agreement on file:
2003/0109017 Filed June 12, 2003
Ballistic Impact resistant Nano-denier fiberous Woven sheet
US P* Patent Application 60/327,684 filed 10-6-01
Intl Patent Application PCT/US 02/12241, 4/15/2002
Anti-ballistic, lightweight Secure cockpit door
US P* Patent Application 60/349,988 filed 1-23-02
Intl Patent Application PCT/US 02/12055, 4/15/2002
Anti-ballistic, wide Angle peep-hole viewer
US P* Patent Application 60/349,990 filed 1-23-02
Intl Patent Application PCT/US 02/12053, 4/15/2002
Security Cockpit door; Integrally vented, pressure Equalized
Intl Patent Application PCT/US 02/12054, 4/15/2002
S.A.G. Turret
US P* Patent Application 60/481,080 filed 7-11-2003
P* - Provisional
++++++++++++++++++++++++++++++++++++++++
END CUT AND TRANSLATE FROM PDF AND PASTED HERE.
GO to USGN.com For more.
Stakddek
This company handled it's short problem:
This is not a recommendation. It's an observation.
++++++++++++++++++++++++++++++++++++++++++++++++++++++
Title: Paid, Inc. Announces New Date for Mandatory Exchange of Stock Certificates
Date: 1/15/2004
WORCESTER, Mass., Jan. 15 /PRNewswire-FirstCall/-- Paid, Inc. (OTC Bulletin Board: PAYD - News) announced today that it has set a second mandatory exchange date of its stock certificates. The new mandatory exchange date is January 16, 2004. Paid, Inc., formerly known as Sales OnLine Direct, Inc. with trading symbol PAID, announced its original mandatory stock certificate exchange date for December 8, 2003, the effective date of Paid, Inc.'s name change, CUSIP number change and trading symbol change. The Company also had announced an amendment to its bylaws to require that all stock certificates held in street name or otherwise must now include the name of the beneficial owner.
The operational processing by the industry for a mandatory exchange that the Company had intended upon its announcement did not occur. Instead, the industry treated the announcements solely as a name and CUSIP change without a mandatory exchange of stock certificates.
After discussing the matter with representatives of Nasdaq and others in the industry, and to facilitate and comply with the Company's bylaws, the Company has determined to set a second mandatory stock certificate exchange date of January 16, 2004, and, as of that date, will use a new CUSIP number of 69561N204.
To effectuate the Company's bylaws change to reflect the name of beneficial owners on all certificates, and as part of the mandatory exchange, the Company anticipates that NASDAQ will announce separately that it will temporarily change trading and quotation of Paid Inc.'s securities on the OTC Bulletin Board ("OTCBB") to a "when-issued" basis, effective January 16, 2004, until such time as Nasdaq determines certificates representing a sufficient number of shares have been exchanged. Paid, Inc.'s stock symbol during the "when issued" period is expected to be PAYDV. The effect of the "when-issued" basis is to take the clearing and settlement of trades temporarily outside of the T+3 rule. The change to a "when-issued" status will prevent clearing and settling trades of Paid, Inc.'s stock during the time that the "when-issued" status is in effect.
The Company expects that the settlement of all trades made after the new effective date will be through physical delivery of stock certificates rather than through DTC.
"We found it unfortunate that the industry did not treat the name and CUSIP change as a mandatory exchange. However, we look forward to carrying out the Company's bylaws to reflect the name of beneficial owners on all certificates, so that we can efficiently and cost effectively communicate with our stockholders," said Greg Rotman, CEO of Paid, Inc.
Stock Certificate Exchange Procedure
Stock Holders
Stockholders who have in their possession paper stock certificates should read and carefully complete the Letter of Transmittal provided by Olde Monmouth Stock Transfer which is available online at http://www.paid.com/investor.shtml. This letter is also available by fax or U.S. Mail by calling 508-791-6710. Then forward the completed Letter of Transmittal together with the stock certificate via an insured, traceable delivery service to the Company's exchange agent, Olde Monmouth Stock Transfer (200 Memorial Parkway, Atlantic Highlands, NJ 07716). Note that there is no need to, and nor should stockholders, endorse the stock certificate.
Stockholders who hold their shares in street name with a broker are urged to confirm with their broker that the broker is including their name on the list of beneficial owners being submitted to the Paid, Inc's exchange agent. These stockholders will not be required to take any further action, unless their broker tells them otherwise.
Broker Dealers
The Company urges brokers dealers with customers that hold Paid, Inc. stock to promptly request from DTC stock certificates representing the number of shares, which reflect their ownership position as of the new effective date, and to submit the certificates along with the beneficial owner information, as described in the Letter of Transmittal. The number of shares represented by the certificates and delivered to the transfer agent must equal the number of shares held by the beneficial owners.
An FAQ with further details relating to this issue is available on Paid's web site at http://www.paid.com/investor.shtml
About Paid, Inc.
Paid's innovative products and services are utilized in online auction management, ecommerce and web site development and hosting. Using proprietary technology, Paid, Inc. is a respected developer of dynamic, cutting edge celebrity web sites and ecommerce storefronts that attract tens of thousands of visitors daily. Paid's AuctionInc brand auction management and shipping calculation software utilized Paid's patent-pending process technologies to streamline back-office and shipping processes for online auctions and e- commerce. Paid's Rotman Auction is an eBay Platinum Powerseller that sells thousands of items -- primarily sports, Hollywood and Americana collectibles and memorabilia -- each week on eBay. The company also builds and maintains large database-driven portals across a broad array of industries. The Company's common stock is traded on the Nasdaq OTC Bulletin Board under the symbol PAYD. For further information visit www.paid.com.
Forward Looking Statements
This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that are based upon current expectations or beliefs, as well as a number of assumptions about future events, including matters related to the Company's operations. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct, including assumptions related to the mandatory exchange, Nasdaq's announcements related to the "when-issued" status, the date in which the stock will return to T+3 trading, whether future settling and clearing of trades will occur electronically or solely through physical delivery, and any other matters related to trading of the Company's stock. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties. In addition, other factors that could cause actual results to differ materially are discussed in the Company's most recent filings, including Form 10-KSB with the Securities and Exchange Commission.
Contact:
Media Contact: Julie Shepherd, Accentuate PR, (815) 479-1833,
Julie@paid.com
Investor Contact, Dennis Evanson, (719) 534-0292, dennis@paid.com
+++++++++++++++++++++++++++++++++++++
Interesting example. USGA management take note please.
USGA has been the victim of an attack by an organization based in England called our-street.com. Our street has filed complaints with the SEC against a number of companies. This is all well and good, BUT --
Our-street (OS) accepts gratuities to finance it's operation. However, if you are the giver of a monthly gratuity, they will give you advance notice of thier research. That 2 day warning only cost you a gratuity of $200.00 per month. If you're unable to be as gratuitous as other parties they will accept your lesser gratuity and give you a few hours notice.
I don't know what the research was that was made public on USGA, but as I was reading the USGA message board on RB I ran across a post by someone who >had just seen news on a crawl about USGA< Well what do you do? I found the news and it was on the M2 wire. It boldly announced that an SEC complaint had been filed re: USGA. Now fearing that this was serious I went to the OS web site and read the complaint. All the usual complaints about a startup, but then the item, they have no patents. Hmmm. SEC complaint, and the patents they said they had don't exist. "Darn I invested in a scam" Man I saw this first let me dump out now.
Now to say I was taken aback by any SEC involvement with a stock I own is an understatement. I dumped on the news. After completing my sale I went back to the RB message board to get some other takes on the news. That's when I found out what OS was about.
I started to reconstruct my position and had managed to get most of it back at a lower price. Of course now I have taxes due on what I felt was a long term hold.
So later that afternoon a retraction of part od the OS press release is issued. There are patents. Sorry but we stand by the rest. Without the patent issue it's really just rehashed basher posts presented in one long post that looks like an official document. Oh and it is an official document if OS is to believed. They did file a complaint with the SEC. They did get a receipt from the SEC that the complaint was received.
Now I have a take on this and I believe it's illegal. The "gratuity givers" (Yeah monthly on a schedule) are given advance notice of the OS activities. (I believe). Heck I don't give a gratuity so I don't know what information they sent to the "co-conspirators". But it was promised on the OS web site to "give two days notice". Now I always figure two days notice on an SEC involvement is pretty good. Now the kicker here is here is this self styled watchdog reporting companies to the SEC and then publicizing it on thier schedule! If they were legit I do not believe they would announce the SEC being requested to investigate. I mean request an investigation, and then turn around and let the chosen few and then the rest of the world in on a possible investigation?
Now OS appears to be part od some Nick Tracy Enterprises over in England. I saw an e-mail address for him that looked like Africa somewhere. I don't even know if he's a real person. You know, Nick tracy or Dick Tracey?? But anyway, this 2 day heads up would tell you:
1. To get out of a position.
2. Set up a short position
3. Do it through your overseas account, and you don't even need shares. (naked)
Now it would be even better if this watchdog errored up and had to withdraw part of it's publicity because it was false. Stock should rebound right? Wonder if they advised the SEC that they were in error on that point. Oh well. So sorry. Faux pas.
Now I really am perturbed about this not just because I got burned, but because some of the people who invested in USGA were doing it through IRA's and Keoughs. Sorta' hard to build those lost funds back up.
The other point and perhaps more critical is USGA is involved in government contracts. You know the kind you can't really publicize. They make armor and have the distribution license on a decontamination foam. Troop protection and Homeland defense. Okay so I'm a sap, but I'm a veteran, and guess what, I invested in a company that was defensive rather that offensive. (Yeah, my heart was in there to a little bit.)
Now we are warned about financial terrorism being part of the Al Queda plan. (and it was directed this time at a possible defense contractor). (Who shorted American and United Airlines before 9/11) I don't think OS was around then, but they would likely think it a cool play. They sure picked a defence entity this time. USGA may be a scam, but a lot of people got involved in a conspiracy to create an incident they would have foreknowledge of so they could profit from it.
Now what you have to ask yourself is:
How would I react? What if my stock #### got publicity like that? What would happen. Would shorts eat my pajamas and come collect the first born child too? Now I view the SEC complaint made as a confidential document. I look on the "contributors" as co-conspirators . I look on OS as a criminal conspiracy waging financial terrorism on the US markets. Now all of us as investors in stocks are combatants in that war. Well guess what. You got a knife and they have nuclear weapons. See the real laugh is they are using the might and power, the reputation of our own US. Government SEC against us. We can't short, etc. Well guys, check out OS and see what you think. Then I suggest you sell every stock you own and we'll all go to Vegas. At least they smile at you there as you lose your money. And they have free drinks! You might even win. But here in the stock market, as long as financial terrorists can go after any stock, just by telling the SEC they think- and then take out a PR to announce they think..., and doing it in collusion with co-conspirators who with two days notice are all set up to collect the those hard earned investment dollars in the Sunny Caymans as they rain from the sky. Now you may do nothing more than read this post and be on to this conspiracy. Or maybe you'll ante up the $200.00 to get that 2 day warning and be in on the "research". But other guys and gals, there be folks out there who want your dollars. If you leave it in stocks right now, they are at more of a risk than normal, because this OS is overseas and you know how quick our government is sometimes. Maybe they'll be quicker this time because of the defence aspect. And when was that wrist slap about mm shorting to go into effect? (I think it only applies to one stock at a time too.)
PS: Incredible hootzpah. Nick Tracy, speaking for Nick Tracy Enterprises, wrote a comment letter to the SEC re: the new rules on short trading. Seem's he feels they make for an orderly market.
So if you guys dig up any info, post it here on I-HUB USGA or Raging Bull USGA and those of us who can are relaying the information to the company and to the SEC. I have no qualms if you copy this report to your congressman or Senator or even your favorite for election. At a time when they are worried about small investors losing faith in the stock markets, well let's see how they react to this problem.
Oh by the way, your invested in #### right? Well I have a friend who paid two hundred bucks and he told me that your stock is on the list. Now don't say I told you. But you better move quick. He told me this morning he got this e-mail. Yeah we're gonna' make money off those other suckers arent we!
Stakddek, who in stating his opinion about the
Our-street.com
organization as he see's it. He is not now nor never has been a subscriber to our-street. Any statements in this post are made from his interpretation of events as he understands them, and he's not a lawyer now and has never aspired to be one. Everything I have stated here is my perception of reality as I know it. I told the truth here, as I know it. In some instances I have expressed an opinion based on my interpretation of the things I conjecture. If you check on this by doing a little due diligence you may conjecture in a similar fashion.
Anyone got some good stock tips????
I do.
Write a letter or copy this e-mail with your comments to the SEC or to your elected officials, or anyone you think cares about your well being. We'll find out who our friends are.
Stakddek
Last post OT about USGA: Thank you all for good wishes and assistance. I am currently unable to post on RB, or even look up another posters' member page. I may have offended some people. Thanks to all who have been so kind. The fraud perpetrated by our-street is reprehensible, especially under the guise of a watchdog. If anyone here has a question about this leave me a post on the I-HUB USGA board and I'll try to answer. (on the I-hub USGA board!)
Stakddek
OT: Miss Scarlet: I will have you know that my tires are fine.
Good Night!
Stakddeck
SEC Address for TIPS or Print outs of Posts that show fore-knowledge of the Our-street conspiracy. In case you want to remain anonymous.
SEC Complaint Center,
USGA - Our Street
Internet Fraud Investigations Dept.
450 Fifth Street, NW,
Washington, D.C.
20549-0213
Mingwan0: Agree but disagree. The current classifications are mandated, but the option was given for additional refinement. The pharma dong research "could include" DNAP ancestry results along with the self-reported race categories. Would be interesting to see the "error rate for self reported vs ancestry" in relation to drug effect. Given the cost of the pharma research, DNAP Ancestry test to each human test subject is negligible. I would, but then I was smart enough to invest here too!
Stakddek (who is only suggesting a rational (to him) footstep in the right direction by researchers.) More data is good. Obviously confusion in self reported race.
Thanks Doug. Please note I suggested it but since you heard from the horses mouth, so to speak, I'll hope that she hasn't already been bombarded with similar contrarian views of her investigative skills. I do feel she was used, but also believe that she was already bent toward her conclusion. Does that make her a "redneck"????
Stakddek
Mingwan0 Did a very detailed commentary on the two major critics (well publicized critics). It is interesting that they are apparentley very aware of Doctor Shriver. Now given that the science that DNAP has is commercial, and it would be beneficial to thier work, perhaps they are a little hot under the academic collar at not being able to use all the inroads DNAP has been perfecting. Very frustrating for them I imagine.
Hopefully Doug who has E-mailed our reporter friend would forward Mingwan0's effort to Ms. ?????? (with Mingwan0's permission of course)in the hope that she may realize she has been "used". Perhaps she had a bias to begin with and sought and perceived the answers that reflected and reinforced that bias. I do not know if that was the case, but it's a thing we all have to watch out for in our daily lives. I find it a little comical that given the racial categories that they do use, and DNAP's ancestry being so more precise, we still are going to hung up on bias, because our own unique perception of "race" is being refined.
I seem to recall that a photodatabase is being created to aid law enforcement to better relate to how broad the categories are under the DNAP results. We can all well remember the "recall" on the first eyecolor testing to retake photos under more controlled circumstance. There maybe a few more of these "negative" press incidents until the process and the promise are fully understood.
PS: I don't think the brokers like it one you release news when they are at lunch! Oh well. I hope at least one of was finishing a softdrink and then sprayed a little beverage out of his nose. But that's just my sadistic aside.
Stakddek
(obligatory pump)
LET'S GO DNAP!
Well we have our first pan publicity. Confusion over the "race" and "ancestry" categories. Oh well Check RB and look on DNAP message list for "CINDY".
Woodcock Again.
++++++++++++++++++++++++++
http://www.nature.com/cgi-taf/DynaPage.taf?file=/nrd/journal/v2/n12/full/nrd1274_fs.html
+++++++++++++++++++++++++
December 2003 Vol 2 No 12 NEWS ANALYSIS
Nature Reviews Drug Discovery 2, 937-938 (2003); doi:10.1038/nrd1274
[231K]
FDA guidance on pharmacogenomics data submission
Donna R. Savage
Donna R. Savage, Washington
A US FDA pharmacogenomics workshop sought to inform and reassure the industry about submitting data
"Much fear exists, but the reality is that most of the pharmacogenomic data currently available is not suitable for regulatory decision making, because it is not well-enough established scientifically." With these words, Janet Woodcock, Director of the Center for Drug Evaluation and Research (CDER) of the US Food and Drug Administration (FDA), challenged more than 500 pharmaceutical company and government representatives from around the world who gathered in Washington, DC, on 13–14 November to discuss the FDA's draft guidance for industry on pharmacogenomic (PG) data submission.
+++++++++++++++PHOTO NOT IMPORTED ++++++++++++++
Janet Woodcock, Director of the CDER.
The draft guidance (http://www.fda.gov/cder/guidance/5900dft.pdf) provides specific criteria and recommendations for submission of PG data (defined as the use of a pharmacogenomic or pharmacogenetic test), which includes submissions for Investigational New Drug Applications, New Drug Applications and Biologic License Applications. Information is provided on what data are needed and how the FDA will or will not use such data in regulatory decisions.
The workshop provided a forum for discussing the draft guidelines, as well as for defining voluntary submission of PG data, the form and process for presenting such data and the regulatory review procedure.
Because of the need for scientific exchange within this new field, the FDA is asking researchers and sponsors to submit research data voluntarily to help the FDA gain experience as the PG field evolves. But apprehension about what the FDA will do with this voluntarily submitted data constitutes the fear among companies that Woodcock referred to.
However, Woodcock stressed that voluntary submission of PG data is being requested because "we need to become more knowledgeable." The goal is to collect much-needed data to establish a framework so that the PG field can move from being a new science to one that is useable and widely utilized (see the editorial on page 935).
Discussion at the workshop centred on the definition of biomarkers and how to handle intellectual property (IP) issues. Biomarker definition was discussed at length because of the perceived lack of clarity about what constitutes a probable, known or valid biomarker. Woodcock offered descriptions for the different categories of biomarker (see Box), which most people agreed were helpful.
Although acknowledging that pharmacogenomics has the potential to improve the drug development process as well as public health, industry representatives remained concerned about IP issues and the proprietary nature of PG data that will be submitted voluntarily. Larry Lesko, director of the FDA's Office of Clinical Pharmacology and Biopharmaceutics, acknowledged the need for the FDA to resolve IP issues and concomitant concerns about patents on research tools.
Early PG results are expected in drug metabolism, because scientific understanding of pharmacogenomics is most advanced in this field. However, GlaxoSmithKline (GSK) has previously indicated its intent to submit, as a test case to the FDA, data supporting abacavir (Ziagen) and related PG technology that tests for a rare human leukocyte antigen type that is predictive of the risk of developing abacavir hypersensitivity in individuals infected with HIV-1. But, because submission is voluntary, companies have not revealed when they plan to start submitting their data.
"The appearance of guidelines in this emerging field is sincerely welcomed by all practitioners," stated Bill Pennie, director of molecular and investigative toxicology and drug safety evaluation at Pfizer. "As with industry, the regulatory community — not just the FDA — has been on a steep learning curve with these new technologies, and the FDA has kept on top of it extraordinarily competently."
Pennie is also chair of the International Life Sciences Institute's (ILSI) Committee on Application of Genomics and Proteomics to Mechanism-Based Risk Assessment. The ILSI consortium has garnered experience in generating and analysing data sets and has offered to share those with the FDA. Collaboration with the ILSI consortium would give the FDA real and genuinely voluntary data that is not proprietary.
The draft guidance has a comment period that lasts the statutory 90 days, until 2 February 2004, at which time the FDA will analyse and incorporate comments, and craft its final guidance.
Boxes
Biomarker definitions
Valid biomarker. A biomarker that is measured in an analytical test system with well-established performance characteristics and for which there is an established framework or body of evidence that elucidates the physiological, toxicological, pharmacological or clinical significance of the test results. (This definition does not fully describe the situation in drug development, in which data are often rapidly evolving and where some data might be proprietary and in single hands.)
Known valid biomarker. A biomarker that is measured in an analytical test system with well-established performance characteristics, and for which there is widespread agreement in the medical or scientific community about the physiological, toxicological, pharmacological or clinical significance of the results.
Probable valid biomarker. A biomarker that is measured in an analytical test system with well-established performance characteristics, and for which there is a scientific framework or body of evidence that seems to elucidate the physiological, toxicological, pharmacological or clinical significance of the test results.
Source: Draft Guidance for Industry: Pharmacogenomic Data Submissions. US FDA.
© 2003 Nature Publishing Group
+++++++++++++++++++++++++++++++++++++++++++++++
Even though DNAP is a giant, we are so far ahead and off in the distance that we appear small!
Stakddek
OLD NEWS I MISSED:
++++++++++++++++++
http://www.clinicaltrialscompliance.com/content.cfm?content_id=35951
+++++++++++++++++++++++++++++ And text from link++++++++++
Clinical Trials Weekly
Week of November 04, 2003
FDA looking for information on interplay of drugs and genes
Volume: 0
Issue: 0
The FDA is asking drug companies to share information with them on how various drugs might interact with the DNA of individual patients, according to the Associated Press (AP). The study of gene and medicine interactions is called pharmacogenomics. The FDA is currently looking to increase its access to pharmacogenomic data by requiring companies to submit some information when they are seeking approval of a new medication. In other cases the FDA will ask companies to submit data on a voluntary basis. The information will be used to "keep up with the new field," the agency's drug chief, Dr. Janet Woodcock told the AP.
+++++++++++++++++++++++++++++++++++
Stakddek. I missed it. Sorry if I'm rehashing old ground.
Cut from Page 7 of 7 of pdf link in my previous message. My comment at end of this cut and paste,
++++++++++++++++++++++++++
>>>>>>>So what's the message we want to give the public about that? Ego genomics Part III, if you will. The
world's first recreational genetic testing service is how they bill themselves, DNAPrint Genomics, a
company in Florida that says it will measure your racial ancestry and racial proportions for you using
DNA markers. Well, why would you want to do that? Perhaps for genealogy or to validate your
eligibility for race-based college admissions or government entitlements. Here's some of their literature
from their website. "Have you ever wondered if you're of purely Indo-European origin, or a blend of
Indo-European or Native American or other ancestry? We can answer that. Capable of determining your
precise ancestral proportions might reveal you're 80 percent African," et cetera, et cetera.
Who is interested in this test? Well, genealogists, the adopted. One customer used the test to hone his
search for an organ donor. Another suspected he was of significant Native American heritage but had no
way to prove it. The test gave him a sound basis by which to claim access to commercial opportunities
reserved for Native Americans. "So whether you're just curious or your goal is to achieve social status of
a particular group, we can help you do this."
Well, again, junk science? I personally don't know. There seems to be a lot of contention within the
genetics community about whether this is realistic and meaningful or not. But it certainly feeds into our
race consciousness in this culture, and you can see ways in which people's motivations for acquiring this
test for themselves, for their children, for their potential spouses, would only go in the wrong direction.
In fact, this is, again, luxury genomics that is a recreational service, but it has already been put to at least
one serious use. They've used the DNAPrint testing procedures on a forensic sample to reorient a search
for a suspect from one race to another.
So here we are. Here's my summary of the issues that I would like to put on your agenda. First is to////////
+++++++++++++++++++++ Above cut from PDF+++++++++++
We have a lot of acceptance to gain. Another comment I noted was one speaker commented that there was more drug reaction variation in "a" racial group, than in the general populous as a whole. Of course this speaker was referring (I believe) to the current self reported "race". (Reminding me of thet High School principal in California he thought he was black).
So it looks like those policy makers need much education. I quess they can't see or admit something that's as plain as the nose on thier face until someone shoves it down into a Petri dish so they get a good closeup. Our acedemia. Killing us softly with thier smiles!
Stakddek
Mention of DNAP, not quite perjorative, but,....
see page 7 of this .pdf file link.
++++++++++++++++
http://www4.od.nih.gov/oba/SACGHS/meetings/June2003/Presentations/Juengst_t.pdf
++++++++++++++++++++++
Stakddek